SCHEMBL3340949

SCHEMBL3340949

O=C(NNc1nc(-c2ccc(N3CCCC3)cc2)cs1)c1ccc(F)nc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.53
GAA P10253 9/20 0.53
KDM4E B2RXH2 8/20 0.53
HTT P42858 5/20 0.53
ALDH1A1 P00352 5/20 0.53
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
LMNA P02545 4/20 0.53
TDP1 Q9NUW8 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MAOA P21397 7/20 0.49
MAPK1 P28482 3/20 0.47
MAOB P27338 2/20 0.43
MMP2 P08253 1/20 0.43
MMP8 P22894 1/20 0.43
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341693 0.88 MAPT (0.69) MAPTGAAKDM4EHTTALDH1A1
SCHEMBL3339179 0.84 MAPT (0.69) MAPTGAAKDM4EHTTALDH1A1
SCHEMBL3337838 0.83 LMNA (0.56) MAPTGAAKDM4EHTTALDH1A1
SCHEMBL3338686 0.81 MAPT (0.56) MAPTGAAKDM4EHTTALDH1A1
SCHEMBL4801252 0.77 MAOA (0.39) MAPTKDM4EALDH1A1MAOAMAPK1
SCHEMBL2753346 0.73 MEN1 (0.69) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL7040444 0.72 CSNK2A1 (0.68) MAPTGAAHTTALDH1A1MEN1
SCHEMBL25769824 0.72 SCD (0.67) MAPTGAAKDM4EHTTALDH1A1
Bromide SCHEMBL6832797 0.71 MEN1 (0.69) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL2358382 0.70 MPL (0.54) MAPTGAAKDM4EHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885GAA 76/4885KDM4E 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.